SUCCESSOR-1
Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
This study is being conducted in two different parts, or stages.
STAGE 1
In Stage 1, there are four planned groups, also called arms. Three of the four arms will receive different dose levels of investigational drug Mezigdomide in combination with bortezomib and dexamethasone, and one arm will receive pomalidomide, bortezomib and dexamethasone.
STAGE 2
In Stage 2, there are two planned arms. One arm will receive investigational drug Mezigdomide (at the selected dose determined by stage 1), and approved treatments Bortezomib and Dexamethasone, and the other arm will receive comparator arm Pomalidomide, Bortezomib and Dexamethasone.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 810 patients (estimated)
- Sponsors
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs), Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1317
- NCT Identifier
- NCT05519085
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.